KR850700216A - 활성성분을 용해시키기 위한 방법 및 이로부터 얻어진 제약 조성물 - Google Patents

활성성분을 용해시키기 위한 방법 및 이로부터 얻어진 제약 조성물

Info

Publication number
KR850700216A
KR850700216A KR1019850700302A KR850700302A KR850700216A KR 850700216 A KR850700216 A KR 850700216A KR 1019850700302 A KR1019850700302 A KR 1019850700302A KR 850700302 A KR850700302 A KR 850700302A KR 850700216 A KR850700216 A KR 850700216A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
active ingredient
composition according
dissolving
composition obtained
Prior art date
Application number
KR1019850700302A
Other languages
English (en)
Other versions
KR930000029B1 (ko
Inventor
제롬 꼬르비에르
Original Assignee
제롬 꼬르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제롬 꼬르비에르 filed Critical 제롬 꼬르비에르
Publication of KR850700216A publication Critical patent/KR850700216A/ko
Application granted granted Critical
Publication of KR930000029B1 publication Critical patent/KR930000029B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

내용 없음

Description

활성성분을 용해시키기 위한 방법 및 이로부터 얻어진 제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 활성성분을 300내지 700의 분자량을 갖는 에틸렌글리콜의 하나 또는 여러가지 중합체에 처음으로 용해시키고, 그다음 이용액을 사전에 pH같이 조정된 수용성매질에 가함을 특징으로 하는 소수성 유기화합물을 용해시키는 방법.
  2. 제1항에 있어서, 유기상이 또한 방부제, 안정제, 향미제, 착색 물질 또는 감미제를 함용함을 특징으로 하는 방법.
  3. 제1항에 있어서, 수용액상은 pH, 무기염, 방부제 및/또는 다른 제약학적―활성화합물을 위해 고정된 값을 결정하기 위한 방법으로 가해짐을 특징으로 하는 방법.
  4. 비경구, 경구, 근육내 또는 피부경로로 투여하여 사용하기 적합한 제1항의 방법에 의해 또는 제1항의 방법으로 얻어진 제약 조성물.
  5. 제4항에 있어서, 눈에 사용하기 위한 눈점적약 또는 용액의 형태임을 특징으로 하는 제약 조성물.
  6. 제4 또는 5항에 있어서, 활성성분의 퍼센트가 0.1내지 25%의 범위임을 특징으로 하는 제약 조성물.
  7. 제4 또는 5항에 있어서, 활성성분이 인도메타신임을 특징으로 하는 제약 조성물.
  8. 제7항에 있어서, 단위투여량당 인도메타신의 퍼센트가 0.1내지 1%의 범위임을 특징으로 하는 제약 조성물.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019850700302A 1984-03-14 1985-03-12 N-아실 인돌류 활성성분의 용해방법 KR930000029B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1279/84 1984-03-14
CH127984 1984-03-14
PCT/FR1985/000050 WO1985004106A1 (fr) 1984-03-14 1985-03-12 Ppocede de solubilisation de principes actifs et compositions pharmaceutiques ainsi obtenues

Publications (2)

Publication Number Publication Date
KR850700216A true KR850700216A (ko) 1985-12-26
KR930000029B1 KR930000029B1 (ko) 1993-01-06

Family

ID=4206704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850700302A KR930000029B1 (ko) 1984-03-14 1985-03-12 N-아실 인돌류 활성성분의 용해방법

Country Status (12)

Country Link
US (1) US4794117A (ko)
EP (1) EP0173729B1 (ko)
JP (1) JPS61501566A (ko)
KR (1) KR930000029B1 (ko)
AT (1) ATE57472T1 (ko)
AU (1) AU573321B2 (ko)
DE (1) DE3580140D1 (ko)
HU (1) HU195918B (ko)
IT (1) IT1200410B (ko)
NO (1) NO165626C (ko)
OA (1) OA08170A (ko)
WO (1) WO1985004106A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607662D0 (en) * 1986-03-27 1986-04-30 Rainsford K D Pharmaceutical formulation
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
EP0306984B1 (en) * 1987-09-11 1992-04-15 Syntex (U.S.A.) Inc. Preservative system for ophtalmic formulations
JPH0723302B1 (ko) * 1989-08-03 1995-03-15
US5290774A (en) * 1989-08-03 1994-03-01 Eisai Co., Ltd. Photostabilizing method for ophthalmic solutions and the resulting ophthalmic solutions therefrom
DE4342907A1 (de) * 1993-12-16 1995-06-22 Bayer Ag Neue cyclische Depsipeptide mit 18 Ringatomen und ihre Verwendung zur Bekämpfung von Endoparasiten
DK0778775T3 (da) * 1994-09-01 1999-09-13 Upjohn Co Parenteral tirilazad-præparat med coopløsningsmiddel
US6274592B1 (en) * 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) * 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10030345A1 (de) * 2000-06-20 2002-01-10 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
ITMI20012135A1 (it) 2001-10-16 2003-04-16 Bioren S A Soluzioni iniettabili pronte all'uso di paracetamolo
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US8992980B2 (en) * 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
FR2851164B1 (fr) 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
WO2007039417A1 (en) * 2005-09-30 2007-04-12 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing meloxicam
US8497303B2 (en) * 2008-01-18 2013-07-30 Dow Global Technologies Llc Method to enhance aqueous solubility of poorly soluble actives
KR20110116194A (ko) 2009-02-03 2011-10-25 선스타 가부시키가이샤 헤스페리딘 함유 조성물
EP4378443A2 (en) 2009-10-12 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Containers for compositions comprising meloxicam
US20110218191A1 (en) * 2010-03-03 2011-09-08 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long term-treatment of kidney disorders in cats
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
MX2013000578A (es) * 2010-07-21 2013-02-21 Alcon Res Ltd Composicion farmaceutica con caracteristicas de solubilidad incrementadas.
GB201321743D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1916432A1 (de) * 1969-03-31 1970-10-08 Dresden Arzneimittel Verfahren zur Herstellung von Injektionsloesungen von therapeutisch wertvollen Benzodiazepinderivaten und ihren Kombinationen mit anderen Wirkstoffen
IL33774A0 (en) * 1970-01-26 1970-03-22 Abic Ltd A water-soluble composition comprising sulfadimidine and pyrimethamine
DK138974B (da) * 1974-02-19 1978-11-27 Ciba Geigy Ag Fremgangsmåde til fremstilling af vandige oxytetracyclinopløsninger til parenteral, peroral og lokal anvendelse.
DE3006024C2 (de) * 1980-02-18 1983-08-04 Solvon Arzneimittel-Vertriebs- Und Lizenzgesellschaft Mbh, 85011 Burgthann Topisches, Indomethacin enthaltendes Arzneimittel in Salbenform

Also Published As

Publication number Publication date
DE3580140D1 (de) 1990-11-22
KR930000029B1 (ko) 1993-01-06
ATE57472T1 (de) 1990-11-15
AU573321B2 (en) 1988-06-02
EP0173729A1 (fr) 1986-03-12
US4794117A (en) 1988-12-27
IT1200410B (it) 1989-01-18
OA08170A (fr) 1987-03-31
AU4064585A (en) 1985-10-11
HU195918B (en) 1988-08-29
JPS61501566A (ja) 1986-07-31
HUT38263A (en) 1986-05-28
NO854461L (no) 1985-11-08
NO165626B (no) 1990-12-03
IT8519873A0 (it) 1985-03-13
EP0173729B1 (fr) 1990-10-17
NO165626C (no) 1991-03-13
WO1985004106A1 (fr) 1985-09-26

Similar Documents

Publication Publication Date Title
KR850700216A (ko) 활성성분을 용해시키기 위한 방법 및 이로부터 얻어진 제약 조성물
ATE47715T1 (de) Stabile salze von sam mit polyanionen.
ES2016159A6 (es) Gel acuoso a base de acido hilauronico y de acido desoxirribonucleico, utilizable en cosmetica, y procedimiento de preparacion.
FI972326A (fi) Uusi amidinonaftyylijohdannainen tai sen suola
KR860003013A (ko) 안정화된 피록시캄 주사용액의 제조방법
DE3679128D1 (de) Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben.
KR850006135A (ko) 안 과 액 제
AU7378587A (en) Benzo{b}thiophene- and benzo{b}furancarboxamide derivatives their preparation, and pharmaceutical compositions containing them
ES2023880T5 (es) Fijador para el cabello.
IE40663L (en) Oxytetracycline solutions
NO940523L (no) Nye pyrazin-derivater
IT1144033B (it) Derivati triciclici e loro sali farmacologicamente attivi e composizioni farmaceutiche che li contengono,nonche' procedimento per la loro preparazione
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR830004849A (ko) 약학적 제제의 제조방법
NO166451C (no) Fremgangsmaate for fremstilling av en loesning av en vannloeselig polymer.
DE69316382D1 (de) Herstellung von derivaten von n-acetyl neuraminicsäure
ATE65395T1 (de) Acetylcystein enthaltendes, festes, wasserloeslisches arzneimittel.
KR860006542A (ko) 안정화된 효소결합체 조성물
KR910005846A (ko) 치약 조성물
HUP9601526A2 (hu) Véralvadásgátló hatású peptidil-arginin-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
KR910005884A (ko) 단백질 수용액
KR880012226A (ko) 외 용 제
KR910019605A (ko) 항진균성 겔제
BE901681A (fr) Rodenticides a base de derives de la phenylpropargylamine.
DE68909619T2 (de) Wasserlösliche Salze der (+)2-(4-fluorphenyl)-alpha-methyl-5-benzoxazolessigsäure und deren Herstellung.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee